MedPath

Development, Validation and Evaluation of a Deprescribing Tool

Not Applicable
Recruiting
Conditions
Elderly
Registration Number
NCT07114094
Lead Sponsor
Indian Council of Medical Research
Brief Summary

The goal of this clinical trial is to learn if a deprescribing tool can help in reducing prescriptions with potentially inappropriate medications (PIMs), in the Indian elderly population. The main question it aims to answer is- Can inappropriate polypharmacy in elderly patients be reduced through development and implementation of a deprescribing tool relevant to the Indian context? Researchers will compare control arm outcome parameters to see if there is a reduction in Proportion of prescriptions with at least one PIM ( Primary outcome parameter).

Participating Prescribers ( Physicians) will be randomized to Control or Intervention arms. Particpating patients will not be randomized, and will receive routine consultation with a Physician who does not use the Deprescribing Tool (Control arm) or a prescriber who uses the Deprescribing tool ( Intervention Arm)

Detailed Description

Rationale: Polypharmacy is common in the elderly and is associated with increased risk of serious adverse events, including falls, cognitive impairment, functional decline, hospitalization, and death. In addition, some of the prescribed drugs may be potentially inappropriate medications (PIM), whose risks outweigh their benefits. It is therefore necessary to review medication intake of the elderly and discontinue or reduce the dose of the ones that are no longer required. This process, termed deprescribing, can reduce prescription of PIMs, improving prescription quality and minimize risks due to potential adverse effects and drug-disease or drug-drug interactions, as well as cost of therapy. Novelty: Although there are many tools for deprescribing, none of these tools has been developed for the Indian context, where there is widespread use of fixed dose combinations (FDCs), use of medicines from different systems of medicines, and high out of pocket expenditure on medicines. Also, some of the medications listed in existing tools are not marketed in India, while some which are commonly prescribed in the country are not listed in the tools. We therefore propose to develop and validate a deprescribing tool for the Indian elderly population, evaluate its impact on prescription quality and risk minimization, as well as explore the facilitators and barriers in the implementation of the tool. Study Design: Multicenter multi-method study. Deprescribing tool will be developed through a modified Delphi method. Prescribers will then be enrolled and randomised to either the control or intervention arm. Prescribers in control arm will prescribe as routine practice, without the aid of the tool. Prescribers in the intervention arm will use the deprescribing tool for medication review and deprescription, if indicated. Elderly patients (≥ 60 years old) of either sex, will be identified by research staff at the OPD registration counter, and approached to consent for the study. Prescriptions of consenting patients (≥ 60 years) will be photographed after consultation with prescriber in either arm. Prescriptions from both arms will be compared for assessment of outcome parameters. Sample size: 1650 (825 per study site) patients will be included evaluation of effectiveness of the tool. To evaluate barriers and facilitators to implementation, in depth interviews will be held with all 30 prescribers (15 at each site). Follow-up: Patients will be followed up at one month telephonically (or in person in case of a routine follow up visit at one month) to inquire about any adverse events, including hospitalization due to any cause. Patients will also be provided with the contact number of a study staff to be contacted in case of any problem within or after the one month follow up period. Expected Outcome: Improved quality of prescribing in the elderly, with reduction in proportion of prescriptions with PIMs, reduction in average number of PIMs prescribed per prescription and reduction of ADRs, drug-disease and drug-drug interactions.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1650
Inclusion Criteria
  • Elderly patients (≥ 60 years) of either sex, visiting the General Medicine/ Community and Family Medicine OPD of the study sites
Exclusion Criteria
  • Patients not willing to participate in the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Primary Outcome Measures
NameTimeMethod
Change in Proportion of prescriptions with at least one PIMFrom enrollment to end of consultation at 30 minutes to 1 hour

Proportion of prescriptions with at least one PIM in the control arm minus proportion of prescriptions with at least one PIM in the intervention arm.

Proportion= Number of prescriptions with at least one PIM ÷Total number of prescriptions included in the respective arm (intervention/control)

Secondary Outcome Measures
NameTimeMethod
Change in Average number of PIMs per prescriptionFrom enrollment to the end of consultation at 30 minutes to 1 hour

Average number of PIMs in control arm minus Average number of PIMs in intervention arm

Average = Number of PIMs ÷ Total number of prescriptions included in the respective arm (intervention/control)

Change in Proportion of prescriptions in which at least one PIM was deprescribedFrom enrollment to the end of consultation at 30 minutes to 1 hour

Proportion of prescriptions in which at least one PIM was deprescribed in the intervention arm minus Proportion of prescriptions in which at least one PIM was deprescribed in the control arm

Proportion=Number of prescriptions in which at least one PIM was deprescribed ÷Total number of prescriptions included in the respective arm (intervention/control)

Change in Average number of Potential ADRs, Drug- Drug Interactions and Drug- Disease InteractionsFrom enrollment to the end of consultation at 30 minutes to 1 hour

Average number of Potential ADRs, Drug- Drug Interactions and Drug- Disease Interactions in the control arm minus Average number of Potential ADRs, Drug- Drug Interactions and Drug- Disease Interactions in the intervention arm

Average: Number of Potential ADRs, Drug- Drug Interactions and Drug- Disease Interactions ÷ Total number of patients in the respective arm (intervention/control)

Change in Average number of Adverse Events at one month1 month

Average number of Adverse Events in the control arm minus Average number of Adverse Events in the intervention arm Average: Number of Adverse Events÷ Total number of patients in the respective arm (intervention/control)

Trial Locations

Locations (2)

St. John's Medical College, Bangalore, India

🇮🇳

Bangalore, Karnataka, India

All India Institute of Medical Sciences Bhopal

🇮🇳

Bhopal, Madhya Pradesh, India

St. John's Medical College, Bangalore, India
🇮🇳Bangalore, Karnataka, India
Dr. Atiya Faruqui Faruqui, MD
Contact
+91 9980018022
atiya.rf@stjohns.in
Dr. Dinesh Kumar Meena, PhD
Contact
+91 7094402215
dinesh.meena8989@gmail.com
Dr. Geetha Francis, MD
Sub Investigator
Dr. Pretesh Kiran, MD
Sub Investigator
Dr. Padmini Devi D, MD
Sub Investigator
Dr. Mangala Rao, MD
Sub Investigator
John Michael Raj, Msc
Sub Investigator
Dr. Atiya Faruqui, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.